Kidney Cancer Causes
Kidney Cancer Causes
Kidney cancer has an unusually clear set of risk factors for a solid tumour, and three of them are common enough to matter at population level: smoking, body weight and blood pressure. The mechanism behind two of those is now well understood, because the commonest subtype is driven by the same oxygen-sensing pathway that these factors disturb. Around one in twenty cases arises in a family with an inherited syndrome, which matters less for the population and more for the individual, because it changes surveillance for relatives.
Smoking and body weight
Smoking is the best established modifiable risk factor for kidney cancer, and the relationship is dose-dependent: risk rises with the number of cigarettes and the number of years, and falls after stopping. What makes it more than a statistical association is that the mechanism is understood — tobacco smoke contains carcinogens that are absorbed into the blood, filtered by the kidney and concentrated in the urine, where they sit in contact with the tubular cells that give rise to most kidney cancers.
Body weight acts through a different route, and the evidence linking it to kidney cancer is unusually consistent. Risk rises steadily as body mass index rises, across populations and in both sexes, and the excess weight is associated with changes in insulin signalling, inflammatory mediators and the same oxygen-sensing pathway that the commonest subtype depends on. There is no threshold below which weight becomes irrelevant, which is the opposite of how patients usually think about it: it is the direction and the duration that matter, not a specific number.
Two implications follow. Both are cumulative, so someone who stops smoking after twenty years is reducing a risk that has partly accrued and has now stopped growing — which is an argument for stopping rather than for dismissing it. And because both act on the same pathway that clear cell tumours depend on, the more accurate way to hold them is not as two separate hazards but as two ways of disturbing one biological pathway.
High blood pressure
High blood pressure is an established risk factor for kidney cancer, and importantly it raises risk independently of body weight — so the association is not simply obesity working through a second route. The relationship is graded: higher pressure and longer duration are associated with higher risk.
Two qualifications keep this in proportion, and both are worth stating because the topic is easy to overread:
- It does not follow that blood pressure medicines cause kidney cancer. Earlier observations suggested one class might, but subsequent evidence has not consistently supported that, and the more robust interpretation is that the underlying high blood pressure is what matters. Stopping treatment to reduce a theoretical risk would be a worse decision than the one it is intended to avoid.
- The relevant issue for patients under treatment is different. Once kidney cancer is being managed, blood pressure control becomes a practical concern rather than a theoretical one, because it protects the kidney function that is being preserved and because some systemic treatments raise blood pressure as a side effect.
The way to hold these two together is this: high blood pressure raises the risk of this cancer whether or not it is treated, and controlling blood pressure protects the kidney you have left. Neither point is a reason to avoid blood pressure medicines, and neither is a reason to assume that taking them removes the risk.
Inherited syndromes and family history
A minority of kidney cancers arise because of an inherited change in a gene, and while this explains only a small share of all cases, it matters disproportionately for the families concerned because it changes what can be done for relatives.
- von Hippel-Lindau disease — an inherited condition affecting the VHL gene, which normally governs the cell’s response to low oxygen. It causes kidney tumours, often in both kidneys and often at a younger age, along with tumours in the eye, brain, spine, adrenal gland and pancreas. There is a specific drug option for the kidney tumours in this condition, and surveillance of the other organs is part of the plan.
- Hereditary papillary kidney cancer — linked to changes in the MET gene, producing papillary tumours that are often multiple and bilateral. MET alterations also matter in non-inherited papillary tumours, where they open a specific targeted option.
- Birt-Hogg-Dubé syndrome — caused by changes in the FLCN gene, associated with kidney tumours of unusual subtypes, together with lung cysts and skin lesions.
- Other inherited conditions — including tuberous sclerosis and conditions involving SDH or FH gene changes, which produce characteristic tumour types with their own surveillance requirements.
When should an inherited cause be suspected? The pattern matters more than any single feature: onset before about the age of 46, tumours in both kidneys, more than one tumour in the same kidney, a family history of kidney cancer, or a pathology report describing an uncommon subtype. Any one of these is a reason to have a genetics discussion, because testing can change the surveillance arranged for the patient and offers screening to relatives who may carry the same change. This is one of the few places in kidney cancer where a single test can change the arrangements for several people.
Long-term kidney disease and dialysis
People who have been on long-term dialysis, and particularly those who have developed acquired cystic disease of the kidney, have a higher risk of kidney cancer than the general population. The cysts that form in kidneys that have stopped working can develop tumours within them, and the risk rises with the number of years spent on dialysis.
There is a genuine difficulty here that is worth naming. Because the kidneys are already abnormal and the patient is already under regular medical care, a new tumour can be absorbed into the background of an existing illness rather than noticed as a change — and because many patients on dialysis have anaemia and other blood abnormalities anyway, the usual warning signs are less useful than in other patients. Some patients on dialysis also lose the ability to produce urine, which removes blood in the urine as an early signal entirely.
The practical response is structural rather than symptomatic: for patients on long-term dialysis or with acquired cystic disease, periodic imaging is part of surveillance rather than a response to symptoms. If you are in this group, the useful question to ask is what your imaging interval is — and if there is not one, whether there should be.
Factors that have not held up
Several commonly suspected causes of kidney cancer have not been confirmed, and each is worth addressing because acting on them can displace attention from the factors that do matter:
- Coffee — repeatedly studied, and no consistent association with kidney cancer has been established once smoking is taken into account.
- Alcohol — the evidence is weak and does not support alcohol as a cause of this cancer.
- Artificial sweeteners — early animal findings were not reproduced in human studies.
- A specific diet or food type — no individual food or nutrient has been established as a cause, and dietary explanations for a person’s own tumour are almost always unhelpful.
- Blood pressure medication as a cause — as described above, the underlying high blood pressure is the established factor, and the medicines themselves have not been consistently implicated.
- Mobile phones and other environmental exposures — no established association with kidney cancer has been demonstrated.
Why does this list matter? Because the three factors that genuinely matter — smoking, body weight and blood pressure — are all things a person can influence, whereas the items above are not. A patient who spends their attention on coffee or sweeteners is spending it on something that will not change the outcome, and may be less inclined to act on the factors that will.
Who is at higher risk
Combining the above produces a picture of the groups in whom suspicion should be higher:
- Current and former smokers, particularly with a long history — the largest single group.
- People carrying excess body weight, where risk rises with the degree and the duration of the excess.
- People with high blood pressure, whether or not it is treated.
- Patients on long-term dialysis, especially with acquired cystic disease of the kidney.
- People with a family history of kidney cancer, or with an inherited syndrome such as von Hippel-Lindau disease.
- People with occupational exposure to trichloroethylene or cadmium, and those with a history of kidney cancer in the other kidney.
- Older adults and men, with risk rising with age and incidence somewhat higher in men.
Two honest qualifications belong at the end. Being in any of these groups does not mean a person will develop the disease — most of them will not. And being in none of them does not exclude it, since a substantial proportion of patients have no identifiable risk factor. This is the same tension as elsewhere in this cluster: no screening programme would find everyone, so the practical approach is to address the factors that can be changed, to keep to the surveillance intervals where a condition calls for surveillance, and to take any renal mass found on a scan seriously. What these measures can realistically achieve is set out on the risk reduction and early detection page.